Media

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial

Oncopeptides receives decision from the U.S. Food and Drug Administration confirming withdrawal of Pepaxto from the U.S. market

Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority

Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results

Oncopeptides – Invitation to presentation of the year-end report 2023

Fusion Pharmaceuticals Enters Into Exclusive Worldwide License Agreement With Heidelberg University And Euratom For Actinium-Based PSMA Targeted Radiotherapy

BONESUPPORT HOLDING AB (publ) – Publishes year end report 2023

Oncopeptides ensures five years extended market exclusivity for Pepaxti in Europe

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress